Chicago
-
Boutique Healthcare Investment Event MedCity INVEST Is Two Months Away. Register Today!
Join MedCity News and nearly 300 healthcare investors, startups, and innovative-minded executives in Chicago at the Ritz Carlton on May 21-22. Space is limited. Secure your spot today to attend!
-
Don’t Miss the Best Boutique Healthcare Investment Conference — Register for MedCity INVEST Today!
MedCity INVEST 2024, scheduled for May 21-22 at the Ritz Carlton hotel in Chicago, is the ideal event to discuss healthcare funding with investors looking for investment opportunities.
-
Do you advise self-insured employers? You Can Help Us!
Take part in this survey and share some of the trends you are seeing among your clients across healthcare, including chronic conditions, behavioral health and navigation.
-
BioPharma, Devices & Diagnostics, Health Tech, Startups
Healthcare Startups, Time is Running Out to Enter the MedCity INVEST Pitch Perfect Contest in Chicago
Are you a biopharma startup focused on oncology? A devices /diagnostics startup focused on cardiology? Or a health tech startup focused on how consumers/employers
are addressing women’s health? If so, submit an application for MedCity INVEST Pitch Perfect by February 29! -
Connect With More Than 50 Healthcare Startups at MedCity INVEST 2024!
Equal parts networking and curated panels covering the latest trends in healthcare investment, MedCity INVEST 2024 is the ideal event to discuss health tech, biopharma, devices and diagnostics investment opportunities. Register today!
-
Network With More Than 50 Healthcare VC firms at MedCity INVEST 2024!
The conference is the premier boutique healthcare investment event in the U.S.
-
This Biotech Startup Just Raised $105M to Extinguish Inflammation at the Source
Cour Pharmaceuticals’ nanoparticles reprogram the immune system to stop inflammation behind autoimmune disease. Three big pharma companies joined the startup’s Series A financing, which will fund clinical trials in type 1 diabetes and myasthenia gravis.
-
Startup Syntax Bio Leverages CRISPR to Transform Cell Therapy Manufacturing
Syntax Bio’s technology platform uses CRISPR to direct stem cells to become a desired cell type in a process that’s more scalable and less expensive than current methods. The startup is raising a Series A round of financing to further demonstrate the potential of its technology.
-
Health Tech, Hospitals, Startups
Rush Launches Program to Scale RPM for Chronic Conditions Management
Chicago-based Rush University System for Health recently struck a partnership with Cadence — the health system is beginning an RPM pilot using the startup’s technology platform and clinicians. Rush will enroll Medicare and Medicaid patients who have one or more of the following chronic conditions: hypertension, congestive heart failure and type 2 diabetes.
-
A Startup Wins the First FDA Approval of a Cell Therapy for Type 1 Diabetes
CellTrans’s Lantidra is now the first FDA-approved cell therapy for type 1 diabetes. The therapy is made from islet cells sourced from deceased donors.
-
Trayt Health Seeks to Increase Access to Diagnoses and Treatments
CEO Malekeh Amini explains how Trayt Health can bridge the gap for patients seeking neurological care.
-
ASCO Recap: Multiple Myeloma Moves, ADC Advances & Brain Cancer Progress
During the annual meeting of the American Society of Clinical Oncology, a cell therapy posted clinical data that could broaden its use in multiple myeloma. In other developments, the class of drugs called ADCs continue to make progress and a novel brain cancer drug has Phase 3 data that support its use as a new treatment option.
-
AstraZeneca, Daiichi Drug Shows Signs It Could Treat a Wide Range of Tumor Types
The HER2 protein targeted by the approved cancer drug Enhertu is found on a wide range of tumors. Interim Phase 2 data reported at the annual meeting of the American Society of Clinical Oncology suggest the AstraZeneca and Daiichi Sankyo drug has potential to treat many of these cancers.
-
How Data for ImmunoGen Drug Could Change the Way Doctors Treat Ovarian Cancer
In a confirmatory Phase 3 test of ImmunoGen’s Elahere, the ovarian cancer drug handily beat chemotherapy with results that clinicians say could make the treatment the new standard of care for certain patients. The data were presented during the annual meeting of the American Society of Clinical Oncology.
-
In Key Study, Servier Drug Delays Brain Cancer in Patients With Few Treatment Options
A Servier drug candidate acquired as part of a $1.8 billion deal kept a particular type of brain cancer from progressing in a Phase 3 clinical trial. The study results were presented during the 2023 annual meeting of the American Society of Clinical Oncology.
-
At ASCO, BioNTech Shows Encouraging Data for Drug That Led to $200M Deal
BioNTech and OncoC4 reported Phase 1/2 data in non-small cell lung cancer for an immunotherapy called gotistobart. Earlier this year, the German company inked a deal to share in the development of the drug in various types of solid tumors.
-
How Hospitals Are Reducing Gun Violence, Protecting Patients and Staff
Hospitals are places of healing, but they have also become sites of gun violence. A panel at the MedCity News INVEST conference discussed the ways hospitals can reduce threats and de-escalate situations before they become violent.